Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1156 - Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK

Date

09 Sep 2017

Session

Poster display session

Presenters

Dan Palmer

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

D. Palmer1, P. Ross2, T. Shah3, D. Yu4, S. Shergill5, K. Patterson6, N. Brereton6, D. Lee6

Author affiliations

  • 1 Department Of Molecular And Clinical Cancer Medicine, University of Liverpool, L69 3BX - Liverpool/GB
  • 2 Department Of Oncology, Guy's & St Thomas' NHS Foundation Trust and King's College Hospital NHS Foundation Trust, London/GB
  • 3 Neuroendocrine Tumour Centre, Queen Elizabeth Hospital Birmingham, Birmingham/GB
  • 4 Department Of Radiology, Royal Free Hospital, London/GB
  • 5 Global Pricing, Reimbursement & Market Access, SIRTEX, London/GB
  • 6 Health Economics Analysis Team, BresMed, S1 2DW - Sheffield/GB
More

Resources

Abstract 1156

Background

Recently presented pivotal trial data (Vilgrain et al. International Liver Congress 2017) has shown that there is no significant difference in overall survival between selective internal radiation therapy (SIRT) with Y-90 resin microspheres (SIR-Spheres®; Sirtex Medical, North Sydney, Australia) and sorafenib for patients with Barcelona Clinic Liver Cancer (BCLC) stage C liver-limited or liver-predominant hepatocellular carcinoma. Y-90 resin microspheres are, however, safer and better tolerated by patients than sorafenib, as well as reducing costs, due to single administration and less frequent and severe side effects. Our aim was to evaluate the cost effectiveness of SIRT using Y-90 resin microspheres versus sorafenib for the treatment of patients with BCLC stage C hepatocellular carcinoma in the UK.

Methods

A cost-minimisation model was built, with equal efficacy assumed between Y-90 resin microspheres and sorafenib. Adverse events data were collected from the Phase III SHARP trial for sorafenib (Llovet et al. N Engl J Med 2008;359:378–90) and from the ENRY study for Y-90 resin microspheres (Sangro et al. Hepatology 2011;54:868–78). Treatment costs were taken from standard UK sources and real-world data from a UK hospital; treatment and adverse events disutilities were taken from published literature. Inputs were validated by UK clinicians and one-way and probabilistic sensitivity analyses were performed.

Results

SIRT using Y-90 resin microspheres is dominant versus sorafenib, providing greater quality-adjusted life years (QALYs) at a lower cost. Y-90 resin microspheres provide 0.0079 (95% confidence interval [CI] 0.0046–0.0111) more QALYs than sorafenib, while saving £8,909 (95% CI £3,257–£14,570). One-way sensitivity analysis showed time on treatment for sorafenib and the work-up and administration costs of Y-90 resin microspheres to be the parameters with the largest influence on results.

Conclusions

In the case of equal efficacy between Y-90 resin microspheres and sorafenib, SIRT using Y-90 resin microspheres is a cost-effective therapy for BCLC stage C hepatocellular carcinoma patients in the UK.

Clinical trial identification

Legal entity responsible for the study

BresMed Health Solutions Ltd

Funding

Sirtex

Disclosure

D. Palmer: Research grants, consultant, sponsored lectures: Sirtex and Bayer. P. Ross: Grants: Sanofi, consultant: Bayer, Celgene Sirtex, sponsored lectures: Bayer, Celgene, Merck, Roche. Travel and meeting attendance: Merck, Bayer, Celgene, Amgen and Servier. T. Shah: Grants: Novartis, and consulted Sirtex. D. Yu: Consultant: Bayer, Boston Scientific, Gore Medical, Sirtex and St Jude Medical. Lectures sponsored: Bayer, Boston Scientific, Gore Medical, Sirtex and St Jude Medical. S. Shergill: Employee of Sirtex. K. Patterson, N. Brereton, D. Lee: Reimbursed for work presented here by Sirtex

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.